Analyst Marc Goodman of Leerink Partners maintained a Buy rating on Mind Medicine (MNMD – Research Report), retaining the price target of $20.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marc Goodman has given his Buy rating due to a combination of factors related to Mind Medicine’s promising pipeline and financial position. The company is making significant progress in its clinical trials, particularly with MM120 for generalized anxiety disorder and major depression disorder, both of which are on track with their Phase 3 studies. The strong Phase 2 data for anxiety and the strategic decision to pursue major depression disorder further bolster confidence in the company’s future prospects.
Additionally, Mind Medicine’s financial health is robust, with approximately $245 million in cash, providing a runway into 2027. This financial stability is further supported by a favorable amendment to their loan agreement with K2 HealthVentures. The company’s focus on executing its programs for generalized anxiety disorder and major depression disorder in 2025, along with its ongoing research into other potential treatments, positions it well for future growth, making it a compelling investment opportunity.
In another report released on May 8, Maxim Group also maintained a Buy rating on the stock with a $18.00 price target.